Background Little information exists regarding pediatric contrast-enhanced US. Objective To assess the safety and feasibility of contrast-enhanced US of pediatric abdominal and pelvic tumors. Materials and methods This prospective study included eight boys and five girls (mean age, 10.8 years) with abdominal or pelvic tumors. Cohorts of three subjects underwent US with perflutren contrast agent at escalating dose levels. Neurological and funduscopic examination, electrocardiography and continuous pulse oximetry were performed before and after contrast administration. Three radiologists independently scored six imaging parameters on pre-and postcontrast sonography. Pediatr Radiol (2012) 42:824-833 DOI 10.1007/s00247-011-2338 agent. Two subjects reported minor, transient symptoms. Postcontrast US parameter scores improved slightly in 8 of 12 subjects. Postcontrast ultrasound inter-reviewer agreement improved slightly for detection of tumor margins (precontrast 0 0.20, postcontrast 0 0.26), local tumor invasion (precontrast 0 -0.01, postcontrast 0 0.10) and adenopathy (precontrast 0 0.35, postcontrast 0 0.44). Conclusions Although our sample size is small, perflutren contrast agents appear to be safe and well tolerated in children. Contrast-enhanced sonography of pediatric abdominal and pelvic tumors is feasible, but larger studies are needed to define their safety and efficacy in children.
Introduction
Children being treated for malignant solid abdominal and pelvic tumors often undergo repeated CT to monitor response. Because children are in a phase of rapid body development and organ growth, their bodies may be more sensitive to the damaging effects of ionizing radiation than those of adults [1, 2] . The carcinogenic effects resulting from diagnostic imaging procedures are stochastic and the probability of secondary malignancy increases with increasing radiation exposure and is cumulative over time. Therefore, radiation-free modalities such as MRI and US should be used whenever possible. Children are excellent candidates for US of abdominal and pelvic structures because the transducer can be positioned near the structure of interest, thereby reducing signal attenuation and artifact. US is also portable, less expensive than CT or MRI, and requires no sedation. However, US images can lack the resolution of CT and MRI in large children with deep-seated structures of interest. Unlike CT and MRI, contrast agents are not routinely used for US to improve visualization of normal and abnormal structures.
Two US contrast agents have been approved by the U.S. Food and Drug Administration (FDA) for use in adult cardiology patients because they substantially improve endocardial border delineation [3] [4] [5] [6] [7] [8] [9] . These "microbubble" agents comprise perfluorocarbon gas (perflutren) encased within an outer shell of protein or phospholipid. The microbubbles approximate the size of an erythrocyte and remain within the vascular space [10] , where they are highly reflective on US. Contrastenhanced US (CEUS) is contraindicated in patients with rightto-left cardiac shunting, which can allow the microbubbles to enter the arterial circulation and potentially cause microvascular occlusion [11] .
The use of US contrast agents has been reported predominantly for adult cardiac and hepatic imaging [3] [4] [5] [12] [13] [14] [15] [16] [17] [18] [19] .
More recently, quantitative CEUS is emerging as a valuable method of monitoring tumor blood flow in preclinical and adult clinical trials [20] [21] [22] [23] [24] . US contrast agents are known to be well-tolerated and safe in adults [25] [26] [27] [28] [29] [30] [31] [32] , but there have been only a few cardiology studies investigating the safety of the intravenous administration of these agents in children [29, 30] . One concern is that contrast-induced microemboli may occur in children due to their potentially different vascular anatomy. Organs most at risk would be the central nervous system, heart and lungs. It is also unknown whether US contrast agents improve sonographic visualization of pediatric abdominal or pelvic structures. Therefore, we sought to assess the safety and feasibility of using a perflutren US contrast agent in children for imaging malignant solid abdominal and pelvic tumors.
Materials and methods

Study design and patients
We investigated an injectable suspension of human serum albumin microspheres encapsulating octafluoropropane gas (Optison™; General Electric Healthcare, Princeton, NJ) with a mean particle size of 2-4.5 μm and a mean pulmonary elimination half-life of 1.3±0.69 (SD) min. This prospective, pediatric dose escalation study was approved by our Institutional Review Board and performed with HIPAA compliance under FDA IND 62,852. Patients aged ≥2 and ≤21 years with a known or suspected solid abdominal or pelvic tumor were eligible. Signed informed consent and assent were provided by patients, parents or guardians, as appropriate. Patients' demographics, primary diagnoses and phase of therapy were extracted from medical records.
The study had two primary objectives: 1) to assess the toxicity profile of the US contrast agent in children and young adults and 2) to determine its optimal dose for visualization of abdominal and pelvic pediatric solid malignancies. The study was closed before the optimal dose could be determined because the contrast agent was voluntarily, temporarily withdrawn from the market due to manufacturing irregularities. During the time that the contrast agent was unavailable, newer contrast specific software was installed on our US machine that made it impractical to return to the original study design. Therefore, we instead assessed the feasibility and value of CEUS for visualization of abdominal and pelvic tumors at several contrast agent dose levels using gray-scale imaging. A secondary objective, to assess the feasibility of quantifying contrast agent flow into pediatric solid tumors, is not addressed here. Each child received two injections of the same dose of contrast agent: the first to assess tumor visualization (primary objective) and the second to address the secondary objective. Both injections were used to assess toxicity. Using a traditional Phase 1 toxicity schema, cohorts of three children were enrolled at escalating dose levels; three subjects were imaged at a single dose level before escalating to the next higher dose (Table 1) . For this contrast agent, the manufacturer's recommended adult dose is 0.5 mL, which may be increased with repeated injections to improve endocardial border delineation [11] . The most recent pediatric cardiology study based dosing of this agent on weight such that children <20 kg received 0.3 mL and ≥20 kg received 0.5 mL [29] . Because there is little data regarding the safety of these agents in children, and at the recommendation of the FDA, the dose was based on body surface area for our safety study, beginning at a very low dose of 0.125 mL/m 2 and escalating in 0.075 mL/m 2 increments to 0.350 mL/m 2 . This approach resulted in doses that were lower than or comparable to those recommended in the pediatric cardiology literature. We also conservatively set the maximal allowable single dose at 2.15 mL/m 2 , approximately half that recommended by the manufacturer for adults [11] . The Cancer Therapy Evaluation Program, Common Toxicity Criteria, Version 2.0, was used to define the stopping rule as 20% of patients with a Grade 3 or 4 adverse event attributable to the contrast agent [33] .
Because CEUS was compared to both precontrast US and contrast-enhanced CT, only children scheduled for US and CT were eligible. Candidates underwent extensive eligibility prescreening and baseline evaluations. To minimize the risk of microemboli, particular attention was paid to the central nervous system, heart and lungs. A complete history and physical were required within 2 weeks before CEUS. Children with known sensitivity to human albumin or blood products, those with past or current evidence of retinopathy, pulmonary hypertension, open heart surgery or cyanotic heart disease and those who required sedation for US or were pregnant, lactating, undergoing intensive care or unable to comply with study requirements were ineligible. We assessed subjects indirectly for cerebral microemboli by funduscopic retinal examination before and after CEUS. Baseline funduscopy was performed within 1 week before CEUS in the first 11 children. Because all post-CEUS retinal findings were normal, we then discontinued funduscopic examinations to avoid causing unnecessary discomfort to the children. We also required a normal 12-lead electrocardiogram (ECG; General Electric, 5500 or 5000 Marquette machine, Milwaukee, WI) and baseline limited neurological examination tailored to assess the cranial nerves, gross motor skills and mentation within 1 week before CEUS. Additional requirements were normal blood pressure, heart rate and respiratory rate, and pulse oximetry showing oxygen saturation ≥96% on room air, within 5 min before contrast agent injection. Subjects were interviewed 5 min before injection to record pre-existing symptoms of illness or discomfort.
Thirteen patients were enrolled between June 2003 and August 2004, when the agent was temporarily, voluntarily, withdrawn from the market. One 20-year-old male was enrolled twice at two dose levels. Two children were excluded from imaging analysis because the US machine's mechanical index was >0.9 during CEUS (see scanning procedure below). Those children were included in the toxicity analysis.
US and CT scanning procedures
In clinical practice, a hand injection of this contrast agent is acceptable; however, to standardize the injection rate for research purposes, we administered the agent (diluted in 2 mL of normal saline for the first eight children and in 1 mL for the remaining five) as a bolus through an indwelling central venous line, using a power injector. The first child's bolus was given at 0.2 mL/s, which was too slow to allow adequate visualization. The second child received the bolus at 0.8 mL/s and the remaining 12, at 1 mL/s. Second injections were administered identically after 10 min. A 50 mL/h continuous infusion of sterile normal saline was administered for 30 min after the second injection. An Acuson Sequoia US machine (Mountain View, CA) using a 4V2, 8C2 or 6C2 MHz transducer (selected for maximum image resolution by the sonographer and principal investigator) was used for precontrast imaging and a 6C2 MHz transducer and the Cadence Contrast Agent Imaging CPS software (Acuson, Mountain View, CA), for contrastenhanced imaging. This software obtained imaging in gray scale at a preset resonant frequency compatible with this contrast agent. For CEUS, the US machine's mechanical index was maintained at ≤0.9 to minimize microbubble destruction. Longitudinal and transverse sweeps through the tumor and abdominal or pelvic structures were obtained before and after the first injection of contrast agent and recorded as 10 s digital cine-clips that were stored on magneto-optical discs for later review. Postcontrast imaging was begun immediately after the injection and continued for approximately 5 to 7 min or until the contrast agent was no longer visible. Because of the broad age range of the intended study population, contrast-enhanced CT, rather than MRI, was chosen as the reference standard since it was believed there was less potential for variable image quality with CT. All CT examinations were performed at our institution on a LightSpeed Ultra helical eight-row detector CT scanner (GE Medical Systems, Milwaukee, WI) with oral and IV contrast material, 5 mm slice thickness and a 1.35:1 pitch. Children were scanned using 120 kVp with the milliampere-second setting adjusted for body weight and a preset noise level of 5. Those able to follow breath-hold instructions (generally ages 6 years and older) were scanned during suspended inspiration. The area scanned included the abdomen and pelvis in nine examinations, the abdomen only in three and the pelvis only in two. CT examinations were performed within a mean of 10 days (range 2-25 days) of the CEUS examinations.
Toxicity monitoring
During CEUS, the children underwent continuous ECG monitoring (Welch-Allen Propaq monitor, Beaverton, OR). Within 5 min after the second injection, an ECG rhythm strip was printed and later interpreted by a cardiologist along with a 12-lead ECG performed within 4 h after CEUS. Oxygen saturation was continuously monitored by pulse oximetry during both injections and for 30 min after the second injection. Blood pressure and heart and respiratory rates were recorded 1 and 5 min after each injection and 30 min after the second injection. The children/guardians were interviewed after each injection and again 24 to 48 h after CEUS to identify any immediate or delayed adverse effects attributable to the contrast agent. Focused neurological examination was performed within 30 min after the second injection in the first 12 children and within 2 h in the remaining two. The heart and lungs were auscultated 30 min after the second injection. Follow-up funduscopy was performed within 24 h after CEUS in the first 8 children and within 4 days in an additional two; one child was lost to ophthalmological follow-up.
Feasibility assessment
We assessed feasibility by using contrast-enhanced CT as the reference standard. After each cohort of three childrenwas imaged, their pre-and post-CEUS and contrastenhanced CT imaging was de-identified and reviewed by three pediatric radiologists with 18, 16 and 10 years of experience, who were blinded to the children's history and primary diagnosis. Each radiologist reviewed, in one sitting, all imaging for each cohort; CT and pre-and post-CEUS images were shuffled to approximate random order. Reviewers graded the conspicuity of lesions, tumor invasion of local structures and associated adenopathy as: definitely present 0 1, probably present 0 2, equivocal 0 3, probably not present 0 4 or definitely not present 0 5. Ability to visualize tumor margins was graded as: excellent (>90% identified) 0 1, well-defined (75%-90% identified) 0 2, moderately defined (50%-74% identified) 0 3, poorly defined (<50% identified) 0 4 and not defined 0 5. For each of these four parameters (conspicuity, local invasion, adenopathy, tumor margins), an US-CT agreement score was calculated for pre-and post-CEUS examinations for each reviewer. The agreement score was defined as 5 minus the absolute difference of scores between US and CT. The higher the score, the better the agreement, with 5 being the highest score indicating identical scores between US and CT (e.g., US 0 4 and CT 0 4, then US-CT agreement score 0 5-|4-4|05). One was the lowest possible score indicating polar opposite US and CT scores (e.g., US 0 5 and CT 0 1, then the US-CT agreement score 0 5-|5-1|01). If the CT score differed among the three reviewers, the median was used for purposes of calculating the reviewer's US-CT agreement scores. Each reviewer also determined the number of solid organ metastases and whether the primary tumor was solid, mixed (approximately half and half) or cystic. A score of 1 was given if the tumor was solid, 2 if mixed and 3 if cystic. A score of 1 was given if there were no metastases, 2 if there was only one metastasis and 3 if more than one. For these two parameters (tumor appearance, number of metastases), the US-CT agreement score was defined as 3 minus the absolute difference of scores between US and CT. The total US-CT agreement score for each child was the sum of the individual parameter scores (conspicuity, local invasion, adenopathy, tumor margins, number of solid organ metastases and solid/ mixed/cystic) from all three reviewers. The pre-and postcontrast US-CT agreement scores for each child were then compared.
Statistical analysis
Descriptive statistics were used for all comparisons described above. We also investigated whether contrast enhancement improved inter-reviewer agreement for individual US parameters by comparing pre-and post-CEUS inter-reviewer agreement using weighted Kappa statistics with a linear weight for categories scaled from 1 to 5. Inter-reviewer agreement was defined as: poor ≤0; slight, 0-0.2; fair, 0.2-0.4; moderate, 0.4-0.6; substantial, 0.6-0.8; almost perfect, 0.8-1.0. All analyses were performed with SAS version 9.2 software (SAS Institute, Cary, NC).
Results
The 13 children underwent a total of 28 injections of US contrast material. Demographics, contrast agent dose and volume, primary diagnosis and tumor site are shown in Table 1 . Of note, six children received clinically relevant doses, i.e. doses comparable to current recommendations for this contrast agent (child 1's second enrollment dose and children 8-12, Table 1 ). Two children had not begun therapy, four were off therapy and had recurrent disease, and Each parameter was scored on a scale of 1 to 5. The a individual parameter US-CT agreement score was defined as 5 minus the absolute difference of scores between US and CT. The higher the score, the better the agreement. 5 is the highest score, indicating identical scores for US and CT (e.g., US 0 4 and CT 0 4, then US-CT agreement score 0 5-|4-4|05); 1 is the lowest score, indicating polar opposite scores by US and CT (e.g., US 0 5 and CT 0 1, then US-CT agreement score 0 5-|5-1|01) a Sum of individual parameter US-CT agreement scores for three reviewers for each subject b The score does not include data for tumor appearance, which could not be evaluated due to technical factors eight were undergoing treatment. Cardiac rate and rhythm, oxygen saturation, blood pressure and respiratory rate remained normal in all children during and 30 min after each contrast injection. Post-CEUS auscultation of the heart and lungs was normal in all subjects, and all post-CEUS cardiac rhythm strips and 12-lead ECGs were interpreted as normal. One 2-year-old boy who received 0.275 mL/m 2 of contrast agent demonstrated possible decreased deep tendon reflex on the post-CEUS neurological examination, but it was not attributed to the contrast agent. The boy was undergoing chemotherapy for retroperitoneal neuroblastoma, and it was unclear whether this potential change reflected technical difficulty in assessing deep tendon reflexes in a 2-yearold or the child's underlying disease or treatment. The boy's other post-CEUS findings were normal. The remaining subjects had no change in neurological findings. None of the 10 children who underwent post-CEUS funduscopy showed evidence of retinal microemboli. Two children reported mild, transient symptoms during contrast agent injection. A 20-year-old young man (who received 0.125 mL/m 2 )
experienced mild tinnitus and lightheadedness, and a 12-year-old boy (who received 0.275 mL/m 2 ) experienced brief taste alteration. One 6-year-old boy (who received 0.20 mL/m 2 ) became hyperactive about 1 h after contrast injection and remained irritable throughout the day and night; he was undergoing chemotherapy for Wilms tumor, and the cause of this reaction was unclear. No other delayed adverse reaction was attributed to the contrast agent.
There was a slight improvement in the average scores for 3 of the 4 individual parameters after administration of contrast material ( Table 2) . Eight of the 12 CEUS examinations showed slight improvement in total US-CT agreement scores compared to precontrast US-CT agreement scores (Table 3) 
Discussion
We have rigorously evaluated 13 children with solid abdominal or pelvic malignancies who received a total of 28 intravenous injections of an US contrast agent (perflutren in human serum albumin microspheres). Although this was a dose escalation study, based on current dosing recommendations for this contrast agent, six of the children received clinically relevant doses [11, 29] . Our toxicity assessments were tailored to detect microembolic events in several organ systems of major concern: the central nervous system, the heart and the lungs. We found that this contrast agent was safe and generally well-tolerated in subjects as young as 2 years of age, children with newly diagnosed or recurrent cancer and those undergoing chemotherapy or radiation therapy.
To assess for cerebral microemboli, we performed retinal funduscopic examinations within 1 day (n08) to 4 days (n02) after CEUS and found no retinal changes or evidence of retinal microemboli. No neurological changes were attributed to the contrast agent. One child became hyperactive after the contrast injection and experienced irritability until the following day. While irritability has been reported as a rare (<0.5%) adverse reaction to this contrast agent in adults, the underlying cause in this case remains unclear and may have been related to the child's underlying disease status or treatment [11] .
None of our patients showed evidence of altered cardiac function, conduction, rate or rhythm. Blood pressure, respiratory rate, cardiac and pulmonary auscultation, and continuous pulse oximetry remained normal in all of the children. Two of the children (15%; 2/13) reported mild symptoms during the administration of contrast agent that resolved within minutes: tinnitus and lightheadedness in one and a Noncontrast-enhanced transverse US image near the porta hepatis shows enlarged metastatic nodes (arrows) and main portal vein (curved arrow). b After administration of 0.56 mL of perflutren contrast agent, the main portal vein is opacified (curved arrow) and the relationship between the portal vein and adjacent node (straight arrows) is well defined. c Contrast-enhanced CT image at the level of the porta hepatis shows the enlarged node (arrows) adjacent to the main portal vein (curved arrow) as demonstrated by CEUS taste alteration in the other. Altered taste was previously reported in 2% (4/203) of adults and 5% (1/20) of children receiving this agent [3, 29] . Tinnitus and lightheadedness have also been reported as rare in adults [11] .
Although we were not able to identify the optimal dose of this contrast agent for imaging pediatric abdominal and pelvic tumors, we found that visualization of imaging parameters improved slightly in two-thirds of our patients after contrast administration. Our study was limited by the heterogeneity of tumor types, tumor sites and body habitus. Because of this inherent variability, a larger study will be necessary to identify a dose that provides optimal tumor and organ enhancement in children. Also, newer contrastspecific software that is now available, with color overlay and subtraction capabilities, should improve lesion conspicuity. Despite these limitations, we have shown that enhancement of various pediatric solid abdominal and pelvic tumors can be subjectively appreciated on CEUS even at low contrast agent doses.
Our preliminary data suggest that this US contrast agent is safe and well tolerated in a range of dosages in children with newly diagnosed, currently treated or recurrent solid abdominal or pelvic malignancies. Further studies using current contrast-specific imaging software are needed to identify the optimal dose and to elucidate which pediatric abdominal and pelvic tumors are best visualized by CEUS. In the future, if CEUS is shown to increase diagnostic confidence, it may be possible to reduce the number and cost of CT scans and MRIs requiring sedation that are needed to monitor patients during therapy. Perhaps more importantly, because microbubble contrast agents remain in the vascular space, they can be used as surrogate markers of tumor blood flow. Because the newest class of anti-cancer agents, anti-angiogenic agents, alter tumor blood flow but may not substantially alter tumor size, CEUS is emerging as a promising modality for assessing response to these agents in adult cancers [20, 21, 34, 35] . Our preclinical studies have shown that quantitation of US contrast agent flow into Fig. 3 Wilms tumor in a 6-year-old boy. a Noncontrastenhanced transverse US image of the primary right renal tumor (arrows). b After administration of 0.25 mL of perflutren contrast agent, there is slight enhancement in the lateral aspect of the tumor (arrows). Note that tumor margin is not well defined on pre-or postcontrast US images. c Contrast-enhanced CT image of the tumor better defines the interface between tumor and normal renal parenchyma (arrows) pediatric murine models of neuroblastoma and rhabdomyosarcoma allows accurate monitoring of changes in tumor blood flow induced by a variety of anti-angiogenic agents [22] [23] [24] .
Conclusion
In this small study, we demonstrated the sonographic visualization of contrast agent flow into a variety of solid pediatric tumors in the clinical setting. We will continue to investigate the feasibility of quantitating US contrast agent flow into pediatric solid tumors in clinical trials. Our safety and imaging findings, coupled with the many advantages of sonography in children, uniquely position CEUS to become a valuable method of assessing solid tumors in pediatric cancer therapy trials. Larger studies are needed to confirm the safety and define the efficacy of these agents.
